학술논문
First-in-human phase i study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Document Type
Article
Author
Postel-Vinay, S.; Aspeslagh, S.; Champiat, S.; Marabelle, A.; Lam, V.K.; Litton, J.K.; Somaiah, N.; Altan, M.; Heymach, J.V.; Ros, W.; Schellens, J.H.M.; Opdam, F.L.; Bauer, T.M.; McKean, M.; Hansen, A.R.; Spreafico, A.; Cho, D.C.; Stephen Hodi, F.; Rahma, O.; Autio, K.A.; Paul, E.M.; Struemper, H.; Ahlers, C.M.; Zhou, H.; Gorman, S.A.; Watmuff, M.; Yablonski, K.M.; Yanamandra, N.; Hoos, A.; Chisamore, M.J.; Schmidt, E.V.; Weber, J.S.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 16 March 2023, 11(3))
Subject
Language
English
ISSN
20511426